Evogene Ltd. (EVGN)

Evogene Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Net Income	-13.5	-14.82	-21.97
Depreciation & Amortization	1.14	1.38	1.3
Stock-Based Compensation	0.65	1.24	1.11
Other Adjustments	1.43	-3.57	-0.47
Change in Receivables	0.67	-0.63	-0.01
Changes in Inventories	-1.02	-1.28	0.49
Changes in Accounts Payable	-0.26	-0.63	0.76
Changes in Accrued Expenses	-0.76	-0.55	0.53
Changes in Unearned Revenue	-0.36	-0.56	-0.29
Changes in Other Operating Activities	-1.5	-0.3	-3.04
Operating Cash Flow	-13.5	-19.7	-21.58
Capital Expenditures	-0.14	-0.63	-0.58
Sale of Property, Plant & Equipment	0.08	0.01	0.03
Purchases of Investments	-0	-17.15	-19.7
Proceeds from Sale of Investments	-	27.34	15.92
Other Investing Activities	17.8	0.05	-0.21
Investing Cash Flow	17.74	9.62	-4.54
Long-Term Debt Repaid	-10	-	-
Net Long-Term Debt Issued (Repaid)	-10	-	-
Issuance of Common Stock	4.28	5.62	8.45
Net Common Stock Issued (Repurchased)	4.28	5.62	8.45
Other Financing Activities	-0.89	-0.97	9.7
Financing Cash Flow	-6.6	4.66	18.15
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.02	-0.05	-0.25
Net Cash Flow	-2.35	-5.47	-8.21
Free Cash Flow	-13.64	-20.33	-22.15
FCF Margin	-353.93%	-364.46%	-742.92%
Free Cash Flow Per Share	-1.73	-3.57	-4.83
Levered Free Cash Flow	-21.38	-19.04	-24.7
Unlevered Free Cash Flow	-16.93	-21.37	-23.07

Updated Mar 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q